ClinicalTrials.gg
Active, not recruitingNCT069595639vHPV-BCGUpdated May 20, 2026

Early Phase Clinical Trial About Therapeutic Biological Product Mix for Treating HPV

An Early Phase 1 interventional study of 9vHPV Vaccine plus BCG Vaccine Mix for percutaneous use in HPV Infection, sponsored by Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair. Active, not recruiting at 1 site in United States. Open to female participants aged 24 Years to 64 Years. Per ClinicalTrials.gov, last updated 2026-05-20.

Sponsored by Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair · Early Phase 1, Interventional, and Health services research

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
24 Years to 64 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 166 studies in Papillomavirus Infections with a site in United States — 32 open to participants now, 60 under way, 5 of them phase 3. Papillomavirus Infections · United States.

Planned enrollment
114th of 132
20 · median 128
Started
2025
with 9 others
Phase 1
7 of 166
none open now
Primary completion
2026-10
later than 15 of 59 live
Registered
153rd of 166
by date

Among the 166 studies in Papillomavirus Infections with a site in United States, this one is the 114th largest by planned enrollment of the 132 interventional ones that give a count, is one of 10 that started in 2025, is one of 7 in phase 1, reaches primary completion later than 15 of the 59 other live ones, and was the 153rd registered.

Papillomavirus Infections

580 studies on the registry are indexed under Papillomavirus Infections; 133 are open to participants now.

Browse Papillomavirus Infections studies →

Open to participants now

32 of the 166 studies in Papillomavirus Infections with a site in United States are open now. Recruiting first, the newest first:

27 more — sign in →

All 32 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 87 Papillomavirus Infections studies recruiting now, 38 (44%) set no upper age limit and 44 (51%) stop at 75 or younger; 19 take children under 18; 36 take healthy volunteers.

This study: 24 Years to 64 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 166 studies in Papillomavirus Infections with a site in United States, or all of them as a file.
02

Study summary

Conducting an early phase clinical trial to assess HPV Antigen Presentation Therapeutic Biological Product Mix activity that suggests the potential for clinical benefit of HPV patients.

  1. Treat Infection of Multiple HPV Virus Strains via Trained Immunity.
  2. Activate human HPV Antigen Presentation Reaction.
  3. The human antigen presenting cells (APCs) can treat the HPV virus protein antigens into small peptide fragments, and then clear HPV virus in vivo.
Read the detailed description
  • Conducting an early phase clinical trial to assess HPV Antigen Presentation Therapeutic Biological Product Mix activity that suggests the potential for clinical benefit of HPV patients
  • 20 Cervical HPV Infection Patients
  • Positive testing HPV by standard PCR assay
  • HPV infection without symptoms
  • No clinical signs indicative of oncology
  • TB negative participant is negative IGRA blood test with TB antigens
  • 9vHPV Vaccine 1.0 mL plus BCG Organism 50 MG Mix
  • By the percutaneous route with the multiple puncture device
  • Negative testing HPV by standard PCR assay after percutaneous 21 days
  • Positive IGRA blood test with HPV protein antigen after percutaneous use 21 days
  • Our trial duration will be 12-week duration.
03

Conditions studied

  • HPV Infection

Keywords

  • HPV
  • Antigen Presentation
  • APC
  • IGRA
  • Trained Immunity
  • Innate Immune Memory
  • Cervical
04

Who can participate

Ages eligible
24 Years to 64 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Conducting an early phase clinical trial to assess HPV Antigen Presentation Therapeutic Biological Product Mix that suggests the potential for clinical benefit of HPV patients.

20 Cervical HPV Infection Patients

Inclusion criteria

Inclusion Criteria:

  • Cervical HPV Infection Patients
  • Positive testing HPV by standard PCR assay
  • HPV infection without symptoms
  • No clinical signs indicative of oncology
  • TB negative participant is negative IGRA blood test with TB antigens

Exclusion criteria

Exclusion Criteria:

  • Pregnant
  • Thrombosis
  • Bleeding
  • Allergy
  • TB positive participant is positive IGRA blood test with TB antigens
  • Symptoms of HPV infection
  • Clinical signs suggestive of other infection
  • Symptoms suggestive of other infection
  • Clinical signs indicative of oncology
  • Evidence of critical illness
05

Study design

Phase
Early Phase 1
Primary purpose
Health services research
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Assess for HPV Antigen Presentation

    Therapeutic Biological Product Mix activity 9vHPV Vaccine 1.0 mL add into BCG Organism 50 MG

    Biological: 9vHPV Vaccine plus BCG Vaccine Mix for percutaneous use

Interventions

  • Biological9vHPV Vaccine plus BCG Vaccine Mix for percutaneous use

    By the percutaneous route with the multiple puncture device - 9vHPV Vaccine 1.0 mL plus BCG Organism 50 MG Mix

    Also known as: 9vHPV Vaccine plus BCG Organism Mix

06

What researchers measure

Primary outcomes

  1. 20 HPV Participants with HPV testing by standard PCR assay

    Negative testing HPV by standard PCR assay after percutaneous 21 days

    Time frame: Duration at least 28 days

  2. 20 HPV Participants with IGRA blood test with HPV protein antigen

    Positive IGRA blood test with HPV protein antigen after percutaneous use 21 days

    Time frame: Duration at least 28 days

  3. 20 HPV Participants with IGRA blood test with TB antigens

    * Negative IGRA blood test with TB antigens before percutaneous use * Positive IGRA blood test with TB antigens after percutaneous use 21 days

    Time frame: Duration at least 28 days

07

Study locations

1 site
  • Medicine Invention Design, Inc.
    Rockville, Maryland 20853, United States
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2025 (actual). Primary completion is estimated for Oct 2026, 17 months after the start.

Of 16 phase 1 interventional studies under Papillomavirus Infections, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 25. This study's planned 17 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 28, 2025
First posted
May 6, 2025
StartActual
Apr 28, 2025
Primary completionEst.
Oct 18, 2026
CompletionEst.
Oct 28, 2026
Last update
May 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06959563
Lead sponsor
Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair
Collaborators
UnitedHealthcare
Responsible party
Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair (M.D., Ph.D., FAPCR, Sponsor-Investigator, Medical Director, IORG Director, Medical Monitor, Safety Officer, IRB Chair, Medicine Invention Design, Inc) — Sponsor-investigator
First posted
May 6, 2025
Start date
Apr 28, 2025
Primary completion
Oct 18, 2026 (estimated)
Completion
Oct 28, 2026 (estimated)
Last update
May 20, 2026

Study contacts

Han ID Xu, MD/PhD/FAPCR
study chair · Medicine Invention Design Incorporation
Han Xu, MD/PhD/FAPCR
study director · Medicine Invention Design Incorporation
Han Xu, MD/PhD/FAPCR
principal investigator · Medicine Invention Design Incorporation

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion